Bausch + Lomb shares are higher as traders position ahead of the company’s newly announced first-quarter 2026 earnings date (April 29, 2026). With the next scheduled update now close, the stock is reacting to a clearer near-term catalyst window rather than a single intraday operational headline. (blankcapitalresearch.com)

The setup into the Q1 print follows a period where management has been emphasizing continued growth and profitability improvement in 2026, including targets for $5.375–$5.475 billion of revenue and $1.0–$1.05 billion of adjusted EBITDA. That guidance frame gives investors defined benchmarks, and a Q1 call is typically where the market tests whether early-year execution supports those full-year targets. (stocktitan.net)

Key focus areas are pace of pharmaceutical growth (including MIEBO), vision care demand trends, and whether margin expansion is tracking in line with the 2026 EBITDA outlook. Any incremental commentary on product cadence and commercial execution can move expectations quickly given BLCO’s mid-cap profile and sensitivity to forward guidance. (stocktitan.net)

Investors will also be listening for any updates on surgical performance following the prior enVista intraocular lens voluntary recall and subsequent return-to-market process, which the company previously tied to enhanced inspections and vendor material standards. While that development is not new today, it remains part of the broader narrative around execution and risk control. (ir.bausch.com)